WHO ICTRP trial
Efficacy and safety of DMX-200 in patients with focal segmental…
ISRCTN72772236 · International Standard Randomised Controlled Trial Number (ISRCTN) · Recruiting
Key facts
| Trial ID | ISRCTN72772236 |
|---|---|
| Public title | Efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis |
| Scientific title | A pivotal Phase III, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB) |
| Primary sponsor | Dimerix Bioscience Pty Ltd |
| Registry | International Standard Randomised Controlled Trial Number (ISRCTN) |
| Recruitment status | Recruiting |
| Study type | Interventional |
| Phase | Phase III |
| Countries | Argentina;Australia;Brazil;Denmark;France;Hong Kong;New Zealand;Spain;Taiwan;United Kingdom;England;Scotland;United States of America |
| Conditions | Focal segmental glomerulosclerosis Urological and Genital Diseases |
| Interventions | Patients will receive either DMX-200 as 120 mg capsules taken orally twice daily (BID) or matching placebo capsules twice daily (BID), over a treatment period of up to 104 weeks. Patients will continue on a stable dose of angiotensin II… |
| Registration date | Jul 7, 2022 |
| Target size | 286 |
| Secondary IDs | 2021-004174-64;NCT05183646;DMX-200-301, IRAS 1004525, CPMS 50927 |
| Registry page | isrctn.com |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: